1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,350 | 13,450 | 23.10. | |
| 13,250 | 13,450 | 23.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | 1.146 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen | |
| 05.08. | Bioventus Inc. Q2 Profit Advances | 2 | RTTNews | ||
| 05.08. | Bioventus Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 05.08. | Bioventus Non-GAAP EPS of $0.22 in-line, revenue of $153.2M misses by $2.44M | 1 | Seeking Alpha | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 05.08. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.08. | Bioventus, Inc.: Bioventus Reports Second Quarter Financial Results | 354 | GlobeNewswire (Europe) | Q2 reported revenue of $153.2 million increased 4%Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted shareNon-GAAP earnings* of $0.22 per diluted... ► Artikel lesen | |
| 29.07. | Biotech Stocks At 52-Week Highs - Incyte Rises With Q2 Results, Pulse Biosciences, Shoulder Innovations, Bioventus, LB Pharmaceuticals | 973 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 28, 2026, driven by key catalysts including positive quarterly results.Incyte Corporation (INCY)Incyte is a... ► Artikel lesen | |
| 24.07. | Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? | 1 | Zacks | ||
| 08.07. | Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know | 3 | Zacks | ||
| 07.07. | Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? | 1 | Zacks | ||
| 23.06. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | 702 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| 04.06. | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Transcript: Bioventus Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 29.05. | Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 21.05. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05. | Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue | 1 | Seeking Alpha | ||
| 06.05. | Bioventus nach starkem Quartal: Gewinnprognose für 2026 angehoben | 5 | Investing.com Deutsch | ||
| 06.05. | Bioventus Q1 2026 slides: earnings beat drives guidance raise | 1 | Investing.com | ||
| 06.05. | Bioventus Non-GAAP EPS of $0.15 beats by $0.08, revenue of $132.1M beats by $2.2M | 2 | Seeking Alpha | ||
| 06.05. | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | 329 | GlobeNewswire (Europe) | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 4,372 | +1,16 % | Dividendenbekanntmachungen (03.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 0,705 GBP 0,8204 EUR AEGON LTD ADR US0076CA1045 0,2455 USD 0,2118 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,916 | +0,90 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Third Quarter 2026 Financial Results on November 4 | ||
| CARDIOL THERAPEUTICS | 1,000 | -0,40 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,700 | -1,60 % | Arbutus Biopharma: FDA hebt klinischen Stopp für AB-101 auf - Aktie legt vorbörslich zu | ||
| CARDIFF ONCOLOGY | 0,800 | 0,00 % | Cardiff Oncology, Inc. - 8-K, Current Report | ||
| ALDEYRA | 0,565 | -3,42 % | H.C. Wainwright bestätigt Aldeyra-Aktie mit "Neutral" und Kursziel von 2 US-Dollar | ||
| DENALI THERAPEUTICS | 16,450 | +0,06 % | Vom Brainshuttle zur Rückenmarksflüssigkeit: Wie Roche, Denali und NurExone Wirkstoffe ins Nervensystem bringen | ||
| ABCELLERA BIOLOGICS | 10,540 | -0,38 % | AbCellera Biologics Inc.: AbCellera to Present at Upcoming Investor Conferences in November 2026 | AbCellera (Nasdaq: ABCL) announced thatthe Company will present at the following investor conferences:
Stifel Healthcare Conference, November 11, 2026
Jefferies Global Healthcare Conference... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 22,750 | -0,13 % | Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure | SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune... ► Artikel lesen | |
| AC IMMUNE | 2,160 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,875 | -2,62 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 30.09.2026 | Das Instrument PYXB GB00BP9LHF23 SCHRODERS PLC LS -,20 EQUITY wird cum Kapitalmassnahme gehandelt am 30.09.2026 und ex Kapitalmassnahme am 01.10.2026 The instrument PYXB GB00BP9LHF23 SCHRODERS PLC LS... ► Artikel lesen | |
| HELUS PHARMA | 9,105 | +0,50 % | Helus Pharma Inc.: Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 | ||
| CYTOMX THERAPEUTICS | 2,128 | +2,46 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| AGENUS | 5,800 | +2,65 % | Agenus auf Chardans 10. Jährlich veranstalteter Healthcare-Konferenz: Strategischer Schwenk zu ROBIN | ||
| ARCTURUS THERAPEUTICS | 9,830 | -0,10 % | Transcript: Arcturus Therapeutics Q2 2026 Earnings Conference Call |
BIOVENTUS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,950 (-7,12 %) liegt der Kurs bei 12,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.